All In Biotech

Drug Trial Radar · NCT00620594

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Dec 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

183

Actual

Start

Dec 21, 2006

Primary completion

Jan 8, 2013

Study completion Jan 8, 2013

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 21, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, phase I/Ib clinical research study with BEZ235, an inhibitor of phosphatidylinositol 3'-kinase (PI3K). The study consists of a dose escalation part followed by a safety dose expansion part: Dose escalation part (advanced solid tumors, including patients with breast cancer being treated with trastuzumab): Patients receive oral BEZ235 once daily on days 1-28 of the first course. Courses will repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of at least 3 patients receive escalating doses of BEZ235, as single agent or in combination with trastuzumab, until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose expected to produce during the first course of treatment dose-limiting toxicity in 33% of patients. Once the MTD has been defined, the safety expansion parts of the trial will be opened for enrollment. Safety dose expansion part (advanced solid tumors, including patients with breast cancer being treated with trastuzumab): Patients will be treated with BEZ235, as single agent or in combination with trastuzumab, given at the MTD, once daily. Treatment of patients will continue until disease progression or occurrence of unacceptable side effects.

Conditions

  • Breast Cancer
  • Advanced Solid Tumors
  • Cowden Syndrome

Interventions

  • BEZ235Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. determine the maximum Tolerated Dose (MTD) of BEZ235 as single agent and in combination with trastuzumab (Dose escalation part)Time frame: at end of study
  2. assess the safety & tolerability of BEZ235 SDS as single agent and in combination with trastuzumab administered to patients at the MTD level (Safety expansion part)Time frame: at end of study

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California at Los Angeles JonssonComprehensiveCancerCtr

    Los Angeles, California

  • Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice

    New Haven, Connecticut

  • Dana Farber Cancer Institute Clinical Trials ProjectManager

    Boston, Massachusetts

  • Nevada Cancer Institute NVCC - Huntsman

    Las Vegas, Nevada

  • Cancer Centers of the Carolinas CCC Faris

    Greenville, South Carolina

  • Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(2)

    Nashville, Tennessee

  • Baylor Health Care System/Sammons Cancer Center Baylor- Sammons

    Dallas, Texas

  • University of Texas/MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2)

    Houston, Texas

  • Tyler Cancer Center TCC

    Tyler, Texas

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Valencia, Valencia, Spain

  • Novartis Investigative Site

    Valencia, Valencia, Spain

  • Novartis Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.